Instability of the Pseudoautosomal Boundary in House Mice
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Title of the Article
Mechanism-Anchored Profiling Derived from Epigenetic Networks Predicts Outcome in Acute Lymphoblastic Leukemia Xinan Yang, PhD1, Yong Huang, MD1, James L Chen, MD1, Jianming Xie, MSc2, Xiao Sun, PhD2, Yves A Lussier, MD1,3,4§ 1Center for Biomedical Informatics and Section of Genetic Medicine, Department of Medicine, The University of Chicago, Chicago, IL 60637 USA 2State Key Laboratory of Bioelectronics, Southeast University, 210096 Nanjing, P.R.China 3The University of Chicago Cancer Research Center, and The Ludwig Center for Metastasis Research, The University of Chicago, Chicago, IL 60637 USA 4The Institute for Genomics and Systems Biology, and the Computational Institute, The University of Chicago, Chicago, IL 60637 USA §Corresponding author Email addresses: XY: [email protected] YH: [email protected] JC: [email protected] JX: [email protected] XS: [email protected] YL: [email protected] - 1 - Abstract Background Current outcome predictors based on “molecular profiling” rely on gene lists selected without consideration for their molecular mechanisms. This study was designed to demonstrate that we could learn about genes related to a specific mechanism and further use this knowledge to predict outcome in patients – a paradigm shift towards accurate “mechanism-anchored profiling”. We propose a novel algorithm, PGnet, which predicts a tripartite mechanism-anchored network associated to epigenetic regulation consisting of phenotypes, genes and mechanisms. Genes termed as GEMs in this network meet all of the following criteria: (i) they are co-expressed with genes known to be involved in the biological mechanism of interest, (ii) they are also differentially expressed between distinct phenotypes relevant to the study, and (iii) as a biomodule, genes correlate with both the mechanism and the phenotype. -
Predicting Clinical Response to Treatment with a Soluble Tnf-Antagonist Or Tnf, Or a Tnf Receptor Agonist
(19) TZZ _ __T (11) EP 2 192 197 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 02.06.2010 Bulletin 2010/22 C12Q 1/68 (2006.01) (21) Application number: 08170119.5 (22) Date of filing: 27.11.2008 (84) Designated Contracting States: (72) Inventor: The designation of the inventor has not AT BE BG CH CY CZ DE DK EE ES FI FR GB GR yet been filed HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR (74) Representative: Habets, Winand Designated Extension States: Life Science Patents AL BA MK RS PO Box 5096 6130 PB Sittard (NL) (71) Applicant: Vereniging voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patiëntenzorg 1081 HV Amsterdam (NL) (54) Predicting clinical response to treatment with a soluble tnf-antagonist or tnf, or a tnf receptor agonist (57) The invention relates to methods for predicting a clinical response to a therapy with a soluble TNF antagonist, TNF or a TNF receptor agonist and a kit for use in said methods. EP 2 192 197 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 192 197 A1 Description [0001] The invention relates to methods for predicting a clinical response to a treatment with a soluble TNF antagonist, with TNF or a TNF receptor agonist using expression levels of genes of the Type I INF pathway and a kit for use in said 5 methods. In another aspect, the invention relates to a method for evaluating a pharmacological effect of a treatment with a soluble TNF antagonist, TNF or a TNF receptor agonist. -
Structural and Numerical Changes of Chromosome X in Patients with Esophageal Atresia
European Journal of Human Genetics (2014) 22, 1077–1084 & 2014 Macmillan Publishers Limited All rights reserved 1018-4813/14 www.nature.com/ejhg ARTICLE Structural and numerical changes of chromosome X in patients with esophageal atresia Erwin Brosens*,1,2,5, Elisabeth M de Jong1,2,5, Tahsin Stefan Barakat3, Bert H Eussen1, Barbara D’haene4, Elfride De Baere4, Hannah Verdin4, Pino J Poddighe1, Robert-Jan Galjaard1, Joost Gribnau3, Alice S Brooks1, Dick Tibboel2 and Annelies de Klein1 Esophageal atresia with or without tracheoesophageal fistula (EA/TEF) is a relatively common birth defect often associated with additional congenital anomalies such as vertebral, anal, cardiovascular, renal and limb defects, the so-called VACTERL association. Yet, little is known about the causal genetic factors. Rare case reports of gastrointestinal anomalies in children with triple X syndrome prompted us to survey the incidence of structural and numerical changes of chromosome X in patients with EA/TEF. All available (n ¼ 269) karyotypes of our large (321) EA/TEF patient cohort were evaluated for X-chromosome anomalies. If sufficient DNA material was available, we determined genome-wide copy number profiles with SNP array and identified subtelomeric aberrations on the difficult to profile PAR1 region using telomere-multiplex ligation-dependent probe amplification. In addition, we investigated X-chromosome inactivation (XCI) patterns and mode of inheritance of detected aberrations in selected patients. Three EA/TEF patients had an additional maternally inherited X chromosome. These three female patients had normal random XCI patterns. Two male EA/TEF patients had small inherited duplications of the XY-linked SHOX (Short stature HOmeoboX-containing) locus. -
A Case of Syndromic X-Linked Ichthyosis with Léri-Weill Dyschondrosteosis
Acta Derm Venereol 2016; 96: 814–815 SHORT COMMUNICATION A Case of Syndromic X-linked Ichthyosis with Léri-Weill Dyschondrosteosis Claire Abasq-Thomas1, Sébastien Schmitt2, Emilie Brenaut1, Chantal Metz3, Jean Chiesa4 and Laurent Misery1 Departments of 1Dermatology and 3Paediatrics, University Hospital of Brest, FR-29609 Brest, 2Department of Genetics, University Hospital of Nantes, Nantes, and 4Department of Genetics, University Hospital of Nîmes, Nîmes, France. E-mail: [email protected] Accepted Feb 1, 2016; Epub ahead of print Feb 2, 2016 Léri-Weill dyschondrosteosis (LWD) is a skeletal dys- tention deficit hyperactivity disorder (ADHP) was suspected plasia marked by disproportionate short stature and initially, but only the patient’s depression, which was probably related to the disease as well as his short stature and skin ap- characteristic Madelung wrist deformity, which is an pearance, was evident after hospitalization. epiphyseal growth plate disturbance characterized by At the dermatology consultation, he presented with dark- dorsal and radial bowing of the radius. In approximately brown scales on the extensor surfaces and a dirty appearance 70% of cases, LWD is caused by haploinsufficiency of the neck. Grey polygonal scales predominated on the lower of the short stature homeobox (SHOX) gene, which limbs. Flexures were affected, but the palms, soles, hairs and nails were spared. An X-linked ichthyosis (XLI) was suspected. maps to the pseudoautosomal region 1 (PAR1) of the Given the associated abnormalities, a contiguous gene syn- sexual chromosomes (Xp22.33 and Yp11.32). Haplo- drome caused by a deletion in Xp was suspected and appropriate insufficiency results from heterozygous mutations and additional investigations were initiated. -
A Strategic Research Alliance: Turner Syndrome and Sex Differences
A strategic research alliance: Turner syndrome and sex differences The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Roman, Adrianna K. San and David C. Page. “A strategic research alliance: Turner syndrome and sex differences.” American journal of medical genetics. Part C, Seminars in medical genetics 181 (2019): 59-67 © 2019 The Author(s) As Published 10.1002/AJMG.C.31677 Publisher Wiley Version Author's final manuscript Citable link https://hdl.handle.net/1721.1/125103 Terms of Use Creative Commons Attribution-Noncommercial-Share Alike Detailed Terms http://creativecommons.org/licenses/by-nc-sa/4.0/ HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Am J Med Manuscript Author Genet C Semin Manuscript Author Med Genet. Author manuscript; available in PMC 2019 March 12. Published in final edited form as: Am J Med Genet C Semin Med Genet. 2019 March ; 181(1): 59–67. doi:10.1002/ajmg.c.31677. A strategic research alliance: Turner syndrome and sex differences Adrianna K. San Roman1 and David C. Page1,2,3 1Whitehead Institute, Cambridge, MA 02142, USA 2Howard Hughes Medical Institute, Whitehead Institute, Cambridge, MA 02142 3Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139 Abstract Sex chromosome constitution varies in the human population, both between the sexes (46,XX females and 46,XY males), and within the sexes (for example, 45,X and 46,XX females, and 47,XXY and 46,XY males). Coincident with this genetic variation are numerous phenotypic differences between males and females, and individuals with sex chromosome aneuploidy. -
Escape from X Chromosome Inactivation and the Female Predominance in Autoimmune Diseases
International Journal of Molecular Sciences Review Escape from X Chromosome Inactivation and the Female Predominance in Autoimmune Diseases Ali Youness 1,†, Charles-Henry Miquel 1,2,† and Jean-Charles Guéry 1,* 1 Infinity-Toulouse Institute for Infectious and Inflammatory Diseases, University of Toulouse, INSERM, CNRS, UPS, 31300 Toulouse, France; [email protected] (A.Y.); [email protected] (C.-H.M.) 2 Arthritis R&D, 92200 Neuilly-Sur-Seine, France * Correspondence: [email protected]; Tel.: +33-5-62-74-83-78; Fax: +33-5-62-74-45-58 † These authors contributed equally to this work. Abstract: Women represent 80% of people affected by autoimmune diseases. Although, many studies have demonstrated a role for sex hormone receptor signaling, particularly estrogens, in the direct regulation of innate and adaptive components of the immune system, recent data suggest that female sex hormones are not the only cause of the female predisposition to autoimmunity. Besides sex steroid hormones, growing evidence points towards the role of X-linked genetic factors. In female mammals, one of the two X chromosomes is randomly inactivated during embryonic development, resulting in a cellular mosaicism, where about one-half of the cells in a given tissue express either the maternal X chromosome or the paternal one. X chromosome inactivation (XCI) is however not complete and 15 to 23% of genes from the inactive X chromosome (Xi) escape XCI, thereby contributing to the emergence of a female-specific heterogeneous population of cells with bi-allelic expression of some X-linked genes. Although the direct contribution of this genetic mechanism in the female susceptibility to autoimmunity still remains to be established, the cellular mosaicism resulting from XCI escape is likely to create a unique functional plasticity within female immune cells. -
A Slippery Boundary
COMMENTARY A slippery boundary Andrew G. Clark* Molecular Biology and Genetics, 107 Biotech Building, Cornell University, Ithaca, NY 14853 he Y chromosome has provided ing Y chromosome indicate greater sim- used to freely recombine between the X one of the greatest challenges in ilarity than any comparison between the and Y, but later the PAB moved to the finalizing complete mammalian X and Y chromosomes. As one moves right, leaving all of amelogenin in the genome sequences in part be- rightwards in Fig. 1, the genealogy nonrecombining region where it is to- Tcause of its unusual relationship with day. To date the time of movement of changes, such that some X- and Y- the X chromosome. Part of the Y chro- linked genes are closest neighbors on the pseudoautosomal boundary, Iwase mosome, known as the pseudoautosomal the tree. In this region, the divergence et al. (1) make use of the X vs. Y diver- region, must pair with the complemen- between the X and Y chromosomes gence, and arrive at an estimate of 27–70 tary region on the X chromosome and drops from Ϸ30% to Ϸ10%, and this million years ago. This is after the mam- undergo recombination, so that the re- drop occurs at a transposable element malian radiation, implying that there sulting crossovers stabilize the sex chro- insertion into the second intron of may have been more than one change in mosomes for proper separation during amelogenin. Because of this relatively the pseudoautosomal boundary. Consis- meiosis. The Y chromosome also bears lower X–Y divergence, Iwase et al. -
A Short Pseudoautosomal Region in Laboratory Mice
Downloaded from genome.cshlp.org on September 29, 2021 - Published by Cold Spring Harbor Laboratory Press Letter A Short Pseudoautosomal Region in Laboratory Mice Jo Perry, Steve Palmer, Anastasia Gabriel, and Alan Ashworth1 The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London SW3 6JB, UK The pseudoautosomal region (PAR) of mammalian sex chromosomes is a small region of sequence identity that is the site of an obligatory pairing and recombination event between the X and Y chromosomes during male meiosis. During female meiosis, X chromosomes can pair and recombine along their entire length; recombination in the PAR is therefore ∼10× greater in male meiosis compared with female meiosis. A consequence of the presence of the PAR in two copies in males and females is that genes in the region escape the process of X-inactivation. Although the structure and gene content of the human PAR at Xq/Yq is well understood, the mouse PAR, which appears to be of independent evolutionary origin, is poorly characterized. Here we describe a yeast artificial chromosome (YAC) contig covering the distal part of the mouse X chromosome, which we have used to define the pseudoautosomal boundary, that is, the point of divergence of X-specific and X-Y–identical sequences. In addition, we have investigated the size of the mouse PAR by integrating a unique restriction endonuclease recognition site just proximal to the pseudoautosomal boundary by homologous recombination. Restriction digestion of this modified DNA and pulsed field gel electrophoresis reveal that the PAR in these cells is ∼700 kb. Thus, the mouse PAR, although small in size, has retained essential sex chromosome pairing functions despite its rapid rate of evolution. -
Analyses of PDE-Regulated Phosphoproteomes Reveal Unique and Specific Camp Signaling Modules in T Cells
Analyses of PDE-regulated phosphoproteomes reveal unique and specific cAMP signaling modules in T cells Michael-Claude G. Beltejar A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Washington 2017 Reading Committee: Joseph Beavo, Chair Shao-en Ong Richard Gardner Program Authorized to Offer Degree: Molecular and Cellular Biology ©Copyright 2017 Michael-Claude G. Beltejar University of Washington Abstract Analyses of PDE-regulated phosphoproteomes reveal unique and specific cAMP signaling modules in T cells Michael-Claude G. Beltejar Chair of the Supervisory Committee: Professor Joseph A. Beavo Department of Pharmacology Specific functions for different cyclic nucleotide phosphodiesterases (PDEs) have not yet been identified in most cell types. Conventional approaches to study PDE function typically rely on measurements of global cAMP, general increases in cAMP-dependent protein kinase (PKA), or exchange protein activated by cAMP (EPAC) activity. Although newer approaches utilizing subcellularly-targeted FRET reporter sensors have helped to define more compartmentalized regulation of cAMP, PKA, and EPAC, they have limited ability to link this regulation to downstream effector molecules and biological functions. To address this problem, we used an unbiased, mass spectrometry based approach coupled with treatment using PDE isozyme- selective inhibitors to characterize the phosphoproteomes of the “functional pools” of cAMP/PKA/EPAC that are regulated by specific cAMP-PDEs (the PDE-regulated phosphoproteomes). In Jurkat cells we found multiple, distinct phosphoproteomes that differ in response to different PDE inhibitors. We also found that little phosphorylation occurs unless at least 2 different PDEs are concurrently inhibited in these cells. Moreover, bioinformatics analyses of these phosphoproteomes provides insight into the functional roles, mechanisms of action, and synergistic relationships among the different PDEs that coordinate cAMP-signaling cascades in these cells. -
Dosage Regulation of the Active X Chromosome in Human Triploid Cells
Dosage Regulation of the Active X Chromosome in Human Triploid Cells Xinxian Deng1, Di Kim Nguyen1, R. Scott Hansen2,3, Daniel L. Van Dyke4, Stanley M. Gartler2,3, Christine M. Disteche1,2* 1 Department of Pathology, University of Washington, Seattle, Washington, United States of America, 2 Department of Medicine, University of Washington, Seattle, Washington, United States of America, 3 Department of Genome Sciences, University of Washington, Seattle, Washington, United States of America, 4 Mayo Clinic College of Medicine, Rochester, Minnesota, United States of America Abstract In mammals, dosage compensation is achieved by doubling expression of X-linked genes in both sexes, together with X inactivation in females. Up-regulation of the active X chromosome may be controlled by DNA sequence–based and/or epigenetic mechanisms that double the X output potentially in response to autosomal factor(s). To determine whether X expression is adjusted depending on ploidy, we used expression arrays to compare X-linked and autosomal gene expression in human triploid cells. While the average X:autosome expression ratio was about 1 in normal diploid cells, this ratio was lower (0.81–0.84) in triploid cells with one active X and higher (1.32–1.4) in triploid cells with two active X’s. Thus, overall X- linked gene expression in triploid cells does not strictly respond to an autosomal factor, nor is it adjusted to achieve a perfect balance. The unbalanced X:autosome expression ratios that we observed could contribute to the abnormal phenotypes associated with triploidy. Absolute autosomal expression levels per gene copy were similar in triploid versus diploid cells, indicating no apparent global effect on autosomal expression. -
Meiotic Consequences of Genetic Divergence Across the Murine Pseudoautosomal Region
Genetics: Early Online, published on January 18, 2017 as 10.1534/genetics.116.189092 Meiotic Consequences of Genetic Divergence across the Murine Pseudoautosomal Region Beth L. Dumont Department of Biological Sciences, Initiative in Biological Complexity, North Carolina State University, Raleigh, NC, 27695 Previous Address: North Carolina State University Initiative in Biological Complexity 112 Derieux Place 3510 Thomas Hall Campus Box 7614 Raleigh, NC 27695-7614 e-mail: [email protected] fax: 919-515-3355 Current Address: The Jackson Laboratory 600 Main Street Bar Harbor, ME 04609 email: [email protected] phone: 207-288-6647 Running Header: Sex chromosome meiosis in hybrid mice Key words: pseudoautosomal region, aneuploidy, recombination, meiosis, Mus musculus 1 Copyright 2017. 1 ABSTRACT 2 The production of haploid gametes during meiosis is dependent on the 3 homology-driven processes of pairing, synapsis, and recombination. On the mammalian 4 heterogametic sex chromosomes, these key meiotic activities are confined to the 5 pseudoautosomal region (PAR), a short region of near-perfect sequence homology 6 between the X and Y chromosomes. Despite its established importance for meiosis, the 7 PAR is rapidly evolving, raising the question of how proper X/Y segregation is buffered 8 against the accumulation of homology-disrupting mutations. Here, I investigate the 9 interplay of PAR evolution and function in two interfertile house mouse subspecies 10 characterized by structurally divergent PARs, Mus musculus domesticus and M. m. 11 castaneus. Using cytogenetic methods to visualize the sex chromosomes at meiosis, I 12 show that intersubspecific F1 hybrids harbor an increased frequency of pachytene 13 spermatocytes with unsynapsed sex chromosomes. -
(12) United States Patent (10) Patent No.: US 9.228,204 B2 Pulst Et Al
USOO9228204B2 (12) United States Patent (10) Patent No.: US 9.228,204 B2 Pulst et al. (45) Date of Patent: Jan. 5, 2016 (54) CONSTRUCTS FOR MAKING INDUCED 2010, O184051 A1 7/2010 Hochedlinger et al. PLURPOTENT STEM CELLS 2010/0279.404 A1 11/2010 Yamanaka et al. 2010.0311171 A1 12/2010 Nakanishi et al. (71) Applicant: University of Utah Research Foundation, Salt Lake City, UT (US) FOREIGN PATENT DOCUMENTS EP 2263705 12/2010 (72) Inventors: Stefan M. Pulst, Salt Lake City, UT KR 2009 OO83761 8, 2009 (US); Sharan Paul, Salt Lake City, UT WO WO 2008,151058 12/2008 (US); Warunee Dansithong, Salt Lake WO WO 2009/007852 1, 2009 City, UT (US) WO WO 2009/092042 T 2009 WO WO 2009,093O22 T 2009 WO WO 2009/096614 8, 2009 (73) Assignee: University of Utah Research WO WO 2009/131262 10/2009 Foundation, Salt Lake City, UT (US) WO WO 2009,133971 11, 2009 WO WO 2009,140655 11, 2009 (*) Notice: Subject to any disclaimer, the term of this WO WO 2009, 149233 12/2009 patent is extended or adjusted under 35 WO WO 2009,152485 12/2009 U.S.C. 154(b) by 0 days. WO WO 2010/017562 2, 2010 WO WO 2010/O19569 2, 2010 WO WO 2010/028O19 3, 2010 (21) Appl. No.: 13/975,004 WO WO 2010/036923 4/2010 (22) Filed: Aug. 23, 2013 OTHER PUBLICATIONS (65) Prior Publication Data Takahashi (Cell, 2006, vol. 126:663-676).* US 2014/O 170752 A1 Jun. 19, 2014 Yu (Science, 2007, vol.